TABLE 2.
Clinical and pathological baseline characteristics of patients eligible for post-nivolumab treatment
| Did not receive further chemotherapy | Received further chemotherapy | p-value | |
| Patients | 76 (40) | 115 (60) | |
| Age at nivolumab initiation | 65.5 (34–86) | 63 (17–84) | 0.11 |
| Sex | 0.78 | ||
| Male | 52 (68) | 76 (66) | |
| Female | 24 (32) | 39 (34) | |
| Smoking history | 0.69 | ||
| Never-smoker | 6 (8) | 10 (9) | |
| Current or ex-smoker | 68 (89) | 104 (90) | |
| Missing data | 2 (3) | 1 (1) | |
| Histology on initial biopsy | 0.91 | ||
| Adenocarcinoma | 46 (61) | 72 (63) | |
| Squamous cell carcinoma | 22 (29) | 30 (26) | |
| Other | 8 (11) | 13 (11) | |
| Stage at diagnosis | 0.57 | ||
| I–II | 7 (9) | 8 (7) | |
| III–IV | 69 (91) | 107 (93) | |
| Lines of therapy before nivolumab | 0.68 | ||
| 0 | 1 (1) | 0 (0) | |
| 1 | 30 (39) | 43 (37) | |
| 2 | 23 (30) | 34 (30) | |
| ≥3 | 22 (29) | 38 (33) | |
| Performance status at nivolumab initiation | 0.028 | ||
| 0 | 10 (13) | 28 (24) | |
| 1 | 35 (46) | 61 (53) | |
| 2 | 21 (28) | 15 (13) | |
| 3 | 1 (1) | 0 (0) | |
| 4 | 0 (0) | 0 (0) | |
| Missing | 9 (12) | 11 (10) | |
| Metastatic sites at nivolumab initiation | 0.49 | ||
| Lung | 31 (41) | 48 (42) | |
| Pleura | 27 (36) | 36 (31) | |
| CNS | 13 (17) | 20 (17) | |
| Liver | 17 (22) | 13 (11) | |
| Adrenal glands | 19 (25) | 15 (13) | |
| Bone | 21 (28) | 26 (23) | |
| Number of nivolumab injections before progression | 5 | 8 | 0.001 |
| Performance status at first tumour evaluation | <0.0001 | ||
| 0 | 0 (0) | 23 (20) | |
| 1 | 20 (26) | 41 (36) | |
| 2 | 19 (25) | 21 (18) | |
| 3 | 16 (21) | 7 (6) | |
| 4 | 7 (9) | 0 (0) | |
| Missing | 14 (18) | 23 (20) | |
Data are presented as n (%), median (range) or median, unless otherwise stated. n=191. CNS: central nervous system. Bold type represents statistical significance.